title: Presentation and outcome of patients with systemic amyloidosis undergoing dialysis.
abstract: OBJECTIVE
  Light chain (AL) and secondary (AA) amyloidosis usually present as a systemic disease frequently involving the kidney and leading to ESRD. Data regarding patients with AA or AL amyloidosis undergoing dialysis remain scarce.
  
  
  METHODS
  We retrospectively studied patients with AA or AL amyloidosis who started dialysis in five French centers between January 1, 1995 and December 31, 2005.
  
  
  RESULTS
  We identified 19 patients with AL and 20 patients with AA amyloidosis undergoing dialysis. Patients with AL amyloidosis had shorter time from diagnosis to dialysis (25.2 versus 69.3 mo, P < 0.05) and more extrarenal amyloidosis, especially cardiac (63.2 versus 5%, P < 0.0001). Mean duration of follow-up was 37.4 and 31.8 mo for patients with AL and AA amyloidosis, respectively. Fifteen patients (78.9%) with AL and three patients (15%) with AA amyloidosis died on dialysis. Median survival was shorter in patients with AL (26 mo) than AA amyloidosis [not definable (ND)] (P < 0.02). Sepsis and cardiac deaths were the main causes of mortality. Prognosis factors for death at 1 yr were AL type (P < 0.01), cardiac amyloidosis [odds ratio (OR) = 18, P < 0.01], heart failure (OR = 8, P < 0.04), and shorter time from diagnosis to dialysis (6.1 versus 56 mo, P < 0.03). Multivariate analysis indicated that AL type (P = 0.02), but not cardiac amyloidosis was independently associated with global mortality.
  
  
  CONCLUSIONS
  Survival of patients with amyloidosis undergoing dialysis, especially AL type, is probably better than previously reported. However, mortality is higher in AL than AA type, especially in the setting of cardiac involvement.
authors.affiliation: Department of Nephrology, AP-HP, Hôpital Necker, Université Paris Descartes, Paris, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Bollée
authors.forename: Bruno
authors.initials: B
authors.lastname: Guery
authors.forename: Dominique
authors.initials: D
authors.lastname: Joly
authors.forename: Renaud
authors.initials: R
authors.lastname: Snanoudj
authors.forename: Benjamin
authors.initials: B
authors.lastname: Terrier
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Allouache
authors.forename: Lucile
authors.initials: L
authors.lastname: Mercadal
authors.forename: Marie-Noëlle
authors.initials: MN
authors.lastname: Peraldi
authors.forename: Béatrice
authors.initials: B
authors.lastname: Viron
authors.forename: Christine
authors.initials: C
authors.lastname: Fumeron
authors.forename: Caroline
authors.initials: C
authors.lastname: Elie
authors.forename: Fadi
authors.initials: F
authors.lastname: Fakhouri
mesh_terms: D000686:Amyloidosis / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D006435:Renal Dialysis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome